Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2008

Open Access 01-03-2008

Hereditary diffuse gastric cancer: association with lobular breast cancer

Authors: Kasmintan A. Schrader, Serena Masciari, Niki Boyd, Sara Wiyrick, Pardeep Kaurah, Janine Senz, Wylie Burke, Henry T. Lynch, Judy E. Garber, David G. Huntsman

Published in: Familial Cancer | Issue 1/2008

Login to get access

Abstract

Hereditary diffuse gastric cancer (HDGC) has been shown to be caused by germline mutations in the gene CDH1 located at 16q22.1, which encodes the cell–cell adhesion molecule, E-cadherin. Not only does loss of expression of E-cadherin account for the morphologic differences between intestinal and diffuse gastric cancer (DGC) variants, but it also appears to lead to distinct cellular features which appear to be common amongst related cancers that have been seen in the syndrome. As in most hereditary cancer syndromes, multiple organ sites may be commonly affected by cancer, in HDGC, lobular carcinoma of the breast (LBC) and possibly other organ sites have been shown to be associated with the familial cancer syndrome. Given the complexity of HDGC, not only with regard to the management of the DGC risk, but also with regard to the risk for other related cancers, such as LBC, a multi-disciplinary approach is needed for the management of individuals with known CDH1 mutations.
Literature
1.
Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 3:354–362
2.
Henson DE, Dittus C, Younes M et al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 7:765–770
3.
Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 6674:402–405CrossRef
4.
Kaurah P, MacMillan A., Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 21:2360–2372CrossRef
5.
Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 2:337–342
6.
Suriano G, Yew S, Ferreira P et al (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 15:5401–5409CrossRef
7.
Oliveira C, Bordin MC, Grehan N et al (2002) Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 5:510–517CrossRef
8.
Brooks-Wilson AR, Kaurah P, Suriano G et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 7:508–517CrossRef
9.
Masciari S, Larsson N, Senz J et al (2007) Germline E-Cadherin mutations in familial lobular breast cancer. J Med Genet 44:726–731PubMedCrossRef
10.
Graziano F, Humar B, Guilford P (2003) The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 12:1705–1713CrossRef
11.
Berx G, Becker KF, Hofler H et al (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 4:226–237CrossRef
12.
Aberle H, Schwartz H, Kemler R (1996) Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 4:514–523CrossRef
13.
Thoreson MA, Anastasiadis PZ, Daniel JM et al (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 1:189–202CrossRef
14.
Xiao K, Oas RG, Chiasson CM et al (2007) Role of p120-catenin in cadherin trafficking. Biochim Biophys Acta 1:8–16
15.
Vleminckx K, Vakaet L Jr, Mareel M et al (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1:107–119CrossRef
16.
Wijnhoven BP, Dinjens WN, Pignatelli M (2000) E-cadherin-catenin cell–cell adhesion complex and human cancer. Br J Surg 8:992–1005CrossRef
17.
Novak A, Dedhar S (1999) Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 5–6:523–537CrossRef
18.
Orsulic S, Huber O, Aberle H et al (1999) E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci Pt 8:1237–1245
19.
Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci Pt 19:3327–3335CrossRef
20.
Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2:681–687CrossRef
21.
De Leeuw WJ, Berx G, Vos CB et al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 4:404–411CrossRef
22.
Becker KF, Atkinson MJ, Reich U et al (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 14:3845–3852
23.
Becker KF, Hofler H (1995) Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 14:1082–1084CrossRef
24.
Machado JC, Soares P, Carneiro F et al (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 79:459–465PubMed
25.
Carneiro F, Oliveira C, Suriano G et al (2007) Molecular pathology of familial gastric cancer. J. Clin. Pathol
26.
Grady WM, Willis J, Guilford PJ et al (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 1:16–17
27.
Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist 1:13–24CrossRef
28.
Rosman DS, Kaklamani V, Pasche B (2007) New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 1:61–73CrossRef
29.
CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 6:1175–1182CrossRef
30.
Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 11:1239–1241CrossRef
31.
Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2:165–167CrossRef
32.
Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. Oncogene 43:5906–5911CrossRef
33.
Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 3:R149–156CrossRef
34.
Allen-Brady K, Camp NJ, Ward JH et al (2005) Lobular breast cancer: excess familiality observed in the Utah Population Database. Int J Cancer 4:655–661CrossRef
35.
Lakhani SR, Gusterson BA, Jacquemier J et al (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 3:782–789
36.
Moll R, Mitze M, Frixen UH et al (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 6:1731–1742
37.
Berx G, Van Roy F (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 5:289–293CrossRef
38.
Berx G, Cleton-Jansen AM, Strumane K et al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 9:1919–1925
39.
Berx G, Cleton-Jansen AM, Nollet F et al (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 24:6107–6115
40.
Droufakou S, Deshmane V, Roylance R et al (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 3:404–408CrossRef
41.
Machado JC, Oliveira C, Carvalho R et al (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 12:1525–1528CrossRef
42.
Humar B, Toro T, Graziano F et al (2002) Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 5:518–525CrossRef
43.
Sarrio D, Moreno-Bueno G, Hardisson D et al (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2:208–215CrossRef
44.
Rahman N, Stone JG, Coleman G et al (2000) Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer 3:568–570
45.
Salahshor S, Haixin L, Huo H et al (2001) Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res 3:199–207PubMedCrossRef
46.
Lei H, Sjoberg-Margolin S, Salahshor S et al (2002) CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 2:199–204CrossRef
47.
Pharoah PD, Guilford P, Caldas C et al (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 6:1348–1353CrossRef
48.
Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 8:479–484CrossRef
49.
Land SR, Wickerham DL, Costantino JP et al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 23:2742–2751CrossRef
50.
Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann NY Acad Sci 99–108
51.
Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 6:1055–1062CrossRef
52.
Robson M, Svahn T, McCormick B et al (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 1:44–51CrossRef
53.
van Kouwen MC, Drenth JP, Oye WJ et al (2004) [18F]Fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 19:6456–6459CrossRef
54.
Shaw D, Blair V, Framp A et al (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 4:461–468CrossRef
55.
Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 25:1904–1909CrossRef
56.
Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 6:873–879CrossRef
57.
Lynch HT, Grady W, Suriano G et al (2005) Gastric cancer: new genetic developments. J Surg Oncol 3:114–133; discussion 133CrossRef
58.
Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 5797:268–274CrossRef
59.
Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 5:1117–1130CrossRef
60.
Jakubowska A, Nej K, Huzarski T et al (2002) BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 8:888–891CrossRef
61.
Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium (1999) J Natl Cancer Inst 15:1310–1316
62.
Figer A, Irmin L, Geva R et al (2001) The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 4:478–481CrossRef
63.
Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 3:700–710CrossRef
64.
Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 18:1365–1372
65.
Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 6:1447–1453CrossRef
66.
Starink TM, van der Veen JP, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 3:222–233
67.
Brownstein M.H., Wolf M., Bikowski J.B. (1978) Cowden’s disease: a cutaneous marker of breast cancer. Cancer 6:2393–2398CrossRef
68.
Hamby LS, Lee EY, Schwartz RW (1995) Parathyroid adenoma and gastric carcinoma as manifestations of Cowden’s disease. Surgery 1:115–117CrossRef
69.
Birch JM, Alston RD, McNally RJ et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 34:4621–4628CrossRef
70.
Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 1:43–47CrossRef
71.
Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1:contribute to genetic predisposition in German gastric cancer patients. J Med Genet 6:e89CrossRef
72.
Kim IJ, Kang HC, Shin Y et al (2004) A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet 49:591–595PubMedCrossRef
73.
Oliveira C, Ferreira P, Nabais S et al (2004) E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 12:1897–1903CrossRef
74.
Kimura K, Shinmura K, Yoshimura K et al (2000) Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res 9:875–879
75.
Shimoyama S, Aoki F, Kawahara M et al (2004) Early gastric cancer development in a familial adenomatous polyposis patient. Dig Dis Sci 2:260–265CrossRef
76.
Dulaimi E, Hillinck J, Ibanez de Caceres I et al (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 18(Pt 1):6189–6193CrossRef
77.
Shinozaki M, Hoon DS, Giuliano AE et al (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 6:2156–2162CrossRef
78.
Geary J, Sasieni P, Houlston R et al (2007) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer
79.
Risinger JI, Barrett JC, Watson P et al (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 9:1836–1843CrossRef
80.
Scott RJ, McPhillips M, Meldrum CJ et al (2001) Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 1:118–127CrossRef
81.
Westenend PJ, Schutte R, Hoogmans MM et al (2005) Breast cancer in an MSH2 gene mutation carrier. Hum Pathol 12:1322–1326CrossRef
82.
Spagnoletti I, Pizzi C, Galietta A et al (2004) Loss of hMSH2 expression in primary breast cancer with p53 alterations. Oncol Rep 4:845–851
83.
Haerer AF, Jackson JF, Evers CG (1969) Ataxia-telangiectasia with gastric adenocarcinoma. JAMA 10:1884–1887CrossRef
84.
Watanabe A, Hanazono H, Sogawa H et al (1977) Stomach cancer of a 14-year-old boy with ataxia-telangiectasia. Tohoku J Exp Med 2:127–131CrossRef
85.
Bigbee WL, Langlois RG, Swift M et al (1989) Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 3:402–408
86.
Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 11:813–822
87.
Milo Y, Deutsch AA, Zahavi S et al (1994) Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast. Postgrad Med J 821:240–241
88.
Puig L, Marti R, Matias-Guiu X et al (1985) Gastric adenocarcinoma in a patient with xeroderma pigmentosum. Br J Dermatol 5:632–633CrossRef
89.
Tsuchiya H, Tomita K, Ohno M et al (1991) Werner’s syndrome combined with quintuplicate malignant tumors: a case report and review of literature data. Jpn J Clin Oncol 2:135–142
90.
Wirtenberger M, Frank B, Hemminki K et al (2006) Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 8:1655–1660
Metadata
Title
Hereditary diffuse gastric cancer: association with lobular breast cancer
Authors
Kasmintan A. Schrader
Serena Masciari
Niki Boyd
Sara Wiyrick
Pardeep Kaurah
Janine Senz
Wylie Burke
Henry T. Lynch
Judy E. Garber
David G. Huntsman
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2008
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9172-6

Other articles of this Issue 1/2008

Familial Cancer 1/2008 Go to the issue

OriginalPaper

Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis

OriginalPaper

Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics

OriginalPaper

Standards of care in diagnosis and testing for hereditary colon cancer

OriginalPaper

A hereditary cancer syndrome seminar: perspective of a Continuing Medical Education (CME) Director

OriginalPaper

Hereditary neoplasia syndromes and the role of the surgeon

OriginalPaper

Pathology of the hereditary colorectal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits